2 results
Approved WMOCompleted
The current study will focus on the effects of an intensive programme of exposure of prism adaptation (i.e. daily exposure during two weeks) and compare these to sham adaptation.
Approved WMOPending
The primary objective is to investigate the effect of bepranemab (45mg/kg and 90mg/kg Q4W) vs placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), a scale used to quantify the severity of symptoms of dementia, as the change from…